
Opinion|Videos|December 23, 2024
Overview: Actionable Alterations in NSCLC
Dr. Joshua Sabari discusses the impact that identification of common and rare actionable alterations has had on personalized therapy selection and improved outcomes for patients with NSCLC.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
IMNN-001 Plus Chemo Cuts MRD Rate in Frontline Ovarian Cancer
5






























